Can-Fite rises as skin drug study reaches interim analysis stage

Can Fite Biopharma

06/07/2026 12:27

** U.S.-listed shares of Can-Fite Biopharma CANF.N rise 2.5% to $4.01 premarket
** The Israel-based drug developer says it completed enrollment of the first 247 patients in a late-stage study of piclidenoson
** The experimental oral drug is for moderate-to-severe plaque psoriasis, a long-term skin disease that causes inflamed, scaly patches
** The study has reached the planned interim analysis stage under a protocol agreed with the U.S. FDA and European Medicines Agency - CANF 
** Says interim data will assess safety and effectiveness; expects results in Q4 2026 or Q1 2027 
** Adds that piclidenoson, taken as a tablet twice daily, has shown a favorable safety profile in more than 1,500 patients across studies 
** As of last close, CANF down 2.3% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))